JP2025513767A5 - - Google Patents

Info

Publication number
JP2025513767A5
JP2025513767A5 JP2024558208A JP2024558208A JP2025513767A5 JP 2025513767 A5 JP2025513767 A5 JP 2025513767A5 JP 2024558208 A JP2024558208 A JP 2024558208A JP 2024558208 A JP2024558208 A JP 2024558208A JP 2025513767 A5 JP2025513767 A5 JP 2025513767A5
Authority
JP
Japan
Prior art keywords
sequence
antigen
antibody
binding fragment
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024558208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513767A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/085417 external-priority patent/WO2023186078A1/zh
Publication of JP2025513767A publication Critical patent/JP2025513767A/ja
Publication of JP2025513767A5 publication Critical patent/JP2025513767A5/ja
Pending legal-status Critical Current

Links

JP2024558208A 2022-04-02 2023-03-31 ｃ－Ｍｅｔに対する抗体及びその使用 Pending JP2025513767A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210345737.1 2022-04-02
CN202210345737 2022-04-02
PCT/CN2023/085417 WO2023186078A1 (zh) 2022-04-02 2023-03-31 针对c-Met的抗体及其用途

Publications (2)

Publication Number Publication Date
JP2025513767A JP2025513767A (ja) 2025-04-30
JP2025513767A5 true JP2025513767A5 (cg-RX-API-DMAC7.html) 2025-06-27

Family

ID=88199461

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024558208A Pending JP2025513767A (ja) 2022-04-02 2023-03-31 ｃ－Ｍｅｔに対する抗体及びその使用

Country Status (8)

Country Link
EP (1) EP4506361A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513767A (cg-RX-API-DMAC7.html)
KR (1) KR20240170835A (cg-RX-API-DMAC7.html)
CN (1) CN119013297A (cg-RX-API-DMAC7.html)
AU (1) AU2023243881A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024012147A (cg-RX-API-DMAC7.html)
WO (1) WO2023186078A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202407983B (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US8101727B2 (en) * 2006-03-30 2012-01-24 Novartis Ag Compositions and methods of use for antibodies of c-Met
JP7325339B2 (ja) * 2017-05-30 2023-08-14 チョン クン ダン ファーマシューティカル コーポレーション 新規な抗ｃ－Ｍｅｔ抗体およびその用途

Similar Documents

Publication Publication Date Title
JP2022535553A5 (cg-RX-API-DMAC7.html)
CN115551889A (zh) 抗cd73抗体及其用途
KR102190548B1 (ko) 항-her2 항체-약물 접합체
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2025514636A5 (cg-RX-API-DMAC7.html)
JP2022526764A5 (cg-RX-API-DMAC7.html)
TW202537975A (zh) 抗體－藥物結合物之製造方法
JP2020529863A (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
JP2021511811A5 (cg-RX-API-DMAC7.html)
KR20190066026A (ko) 항 her2 항체-약물 콘주게이트 투여에 의한 내성암의 치료
JP2022533418A5 (cg-RX-API-DMAC7.html)
RU2011115117A (ru) Нацеленные средства связывания, направленные на dll4, и их применение
JP7094893B2 (ja) エンドシアリン結合抗体
JP2010535713A5 (cg-RX-API-DMAC7.html)
JP2020527332A5 (cg-RX-API-DMAC7.html)
US10358498B2 (en) Human anti-FGFR4 antibody
JP2013534515A5 (ja) 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体
US20150175712A1 (en) Antagonist to an enzyme and/or a metabolite of the kynurenine pathway
JP2025512119A5 (cg-RX-API-DMAC7.html)
CN115210261A (zh) 抗半乳糖凝集素-9抗体及其用途
JP2024532836A5 (cg-RX-API-DMAC7.html)
JP2025513767A5 (cg-RX-API-DMAC7.html)
Wang et al. Construction of a novel TROP2/CD3 bispecific antibody with potent antitumor activity and reduced induction of Th1 cytokines
JP2026511090A (ja) 癌治療における患者選択のためのＣＥＡＣＡＭ５ ｍＲＮＡアッセイ
CN121517560A (zh) 一种双特异性抗体及其应用